Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last week:

‍Blogs :

Panelists discuss the role of venetoclax-ibrutinib across various patient populations.

Asciminib Shows Better Safety and Tolerability Than TKIs in Newly Diagnosed CML

Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTK Inhibitor Treatment Options

‍Also at MCH the News and Tweets never stop flowing!

Join Us at www.mycancerhaven.org

‍The Team @ MCHFollow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.